Miraqules, a biotechnology company based in Bengaluru, is set to showcase its innovative blood clotting technology at TechCrunch Disrupt 2025 from October 27 to 29, 2025, in San Francisco. Founded by CEO Sabir Hossain, the company has developed a unique nanotechnology that mimics natural blood clotting proteins. This breakthrough product could have significant implications for trauma care and emergency medicine.
The technology, which comes in a powder form, rapidly generates fibrous compounds at room temperature. When applied to a bleeding wound, it can absorb blood efficiently, halting bleeding in as little as one to two minutes. “This is a product that will give you feedback instantly,” Hossain explained. “If there is a person bleeding, you apply it, and the bleeding stops.”
Hossain’s journey into biotechnology was inspired by a personal tragedy. A near-fatal accident involving his father highlighted the need for effective blood clotting solutions. Hossain pursued graduate studies in biomedical engineering, initially working on biomaterials. Despite facing challenges in his research, he discovered a method to create a powder from dismantled particles that would ultimately prove effective in blood clotting.
The technology was born when Hossain collaborated with a team struggling to mix their blood clotting solutions. After introducing his powder, they observed rapid clotting within five to ten seconds. This pivotal moment led to the formation of Miraqules, as Hossain and childhood friend Mubeen Midda began developing the technology for practical applications.
Miraqules has achieved considerable milestones, securing 11 patents across seven countries, including India, the United States, and Israel. The company is currently piloting its technology at a trauma care center in India and anticipates receiving regulatory approval in India within the next few months. Additionally, they are on track to obtain clearance from the U.S. Food and Drug Administration (FDA) in 2026.
Hossain noted the importance of early engagement with the FDA, utilizing a pre-submission process to gather feedback on necessary steps for product approval. Remarkably, Miraqules has achieved these advancements with less than $700,000 in capital, primarily sourced from grants.
As Miraqules continues to develop its technology, the company has attracted interest from ten hospital chains in India and the Israeli Defense Forces. The upcoming TechCrunch Disrupt event offers an opportunity for attendees to learn more about Miraqules and witness additional startup pitches, workshops, and networking opportunities that can drive business growth.
This showcase not only highlights Miraqules’ promising technology but also underscores the potential for innovation within the biotech industry. As the company prepares for its presentation at TechCrunch Disrupt, it aims to further its mission of improving emergency medical responses and saving lives.
